Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
Weimin Li(Sichuan University), Robert L. Ferris(University of Pittsburgh), Jiabu Ye(AstraZeneca (Japan)), Nicholas Holoweckyj(AstraZeneca (Japan)), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Todd Hembrough(OncoPlex Diagnostics (United States)), Rajiv Raja(AstraZeneca (United States)), Lisa Licitra(University of Milan), Katia Real(AstraZeneca (United Kingdom)), Nassim Morsli(Boehringer Ingelheim (France)), Jagdish Shetty(AstraZeneca (United States)), Jill Walker(AstraZeneca (United Kingdom)), Robert I. Haddad(Georgetown University), Han Si(AstraZeneca (United States)), Philip He(AstraZeneca (Japan)), Qu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Sophie Wildsmith(AstraZeneca (United Kingdom)), Paul Scorer(Centro de Pesquisas Oncológicas), Alejandro Yovine(AstraZeneca (United Kingdom))
Cited by 27
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k